Transforming Cancer Care: Novotech Releases Report on Radiopharmaceuticals Global Clinical Trials Landscape
26 juin 2024 16h41 HE
|
Novotech
Transforming Cancer Care: Novotech Releases Report on Radiopharmaceuticals Global Clinical Trials Landscape
ITM ernennt Dr. Andrew Cavey zum CEO, um das weitere Wachstum des Unternehmens voranzutreiben
20 juin 2024 05h00 HE
|
ITM Isotope Technologies Munich SE
Dr. Cavey verfügt über langjährige Berufserfahrung in der radiopharmazeutischen Industrie und wird die Weiterentwicklung von ITMs Pipeline und das Unternehmenswachstum maßgeblich unterstützen....
ITM Appoints Dr. Andrew Cavey as CEO to Lead Organization in its Next Stage of Growth
20 juin 2024 05h00 HE
|
ITM Isotope Technologies Munich SE
With a significant track record of success in the radiopharmaceutical industry, Dr. Cavey will help accelerate ITM’s pipeline and business growth Garching /...
ITM Raises €188m to Enhance Radiopharmaceutical Pipeline and to Strengthen Leading Position in Medical Radioisotope Manufacturing
06 juin 2024 05h00 HE
|
ITM Isotope Technologies Munich SE
Proceeds to support development of ITM’s targeted radiopharmaceutical pipeline and preparations for potential market launch of phase III lead candidate, ITM-11, as it nears clinical read-out Funds...
Lantheus Announces Executive Appointments to Accelerate Innovation
15 mai 2024 16h30 HE
|
Lantheus Holdings, Inc.
Jeffrey S. Humphrey, MD appointed Chief Medical Officer;Jean-Claude Provost, MD named Chief Science Officer BEDFORD, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”)...
ITM Appoints Dr. Danielle Meyrick as Chief Medical Officer
07 mai 2024 05h00 HE
|
ITM Isotope Technologies Munich SE
Leveraging profound knowledge in radiopharmaceutical drug development and commercial planning, Dr. Meyrick will lead the medical team in further developing and delivering on ITM's pipeline...
ITM Obtains Manufacturing License in the U.S.
01 févr. 2024 07h00 HE
|
ITM Isotope Technologies Munich SE
License will support ITM’s efforts in preparing for the commercialization of its diagnostic and therapeutic radiopharmaceutical pipeline across the U.S. Garching / Munich and...
ITM Appoints Dr. Mark Harfensteller as Member of its Executive Board
16 janv. 2024 05h00 HE
|
ITM Isotope Technologies Munich SE
Garching / Munich, Germany, January 16, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Dr. Mark Harfensteller to its...
Radiopharmaceuticals Market Size Worth USD 14.45 Billion in 2032 | Emergen Research
15 janv. 2024 08h00 HE
|
Emergen Research
Vancouver, Jan. 15, 2024 (GLOBE NEWSWIRE) -- The global radiopharmaceuticals market size was USD 5.30 Billion in 2022 and is expected to register a rapid revenue CAGR of 10.6% during the forecast...
QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee
14 nov. 2023 07h30 HE
|
QSAM Biosciences Inc.
Austin, TX, Nov. 14, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing therapeutic radiopharmaceuticals for the treatment of primary and secondary bone cancer and...